Industry Veteran and VC Investor Strengthen the BTB Therapeutics Board
BTB Therapeutics, a clinical-stage drug development company working on non-opioid pain medicine ENDOPIN, has announced two new additions to its board of directors. David R. Snyder, a retired partner from Pillsbury Winthrop Shaw Pittman LLP with over 30 years of experience in corporate finance and M&A, and Dr. Nobuhiro Yagi, Executive Officer at Kyoto University Innovation Capital, have joined the board.
Snyder, who currently serves as Vice Chairman and Lead Independent Director at PriceSmart (PSMT), brings extensive legal expertise and corporate governance experience. Dr. Yagi contributes 18 years of experience from Kyowa Kirin in biopharmaceutical R&D and business development, along with research experience from various prestigious institutions.
Both appointments align with BTB's focus on developing non-opioid analgesics and RNA splicing modifiers for rare diseases.
BTB Therapeutics, un'azienda di sviluppo farmaceutico in fase clinica che lavora su medicinali per il dolore non oppioidi ENDOPIN, ha annunciato due nuove aggiunte al suo consiglio di amministrazione. David R. Snyder, un partner in pensione di Pillsbury Winthrop Shaw Pittman LLP con oltre 30 anni di esperienza in finanza aziendale e M&A, e Dr. Nobuhiro Yagi, Direttore Esecutivo presso Kyoto University Innovation Capital, si sono uniti al consiglio.
Snyder, che attualmente ricopre il ruolo di Vice Presidente e Direttore Indipendente Principale presso PriceSmart (PSMT), porta con sé una vasta esperienza legale e in governance aziendale. Il Dr. Yagi contribuisce con 18 anni di esperienza in R&D biopharmaceutico e sviluppo commerciale da Kyowa Kirin, insieme a un'esperienza di ricerca in varie istituzioni prestigiose.
Entrambi gli incarichi sono in linea con l'obiettivo di BTB di sviluppare analgesici non oppioidi e modificatori di splicing dell'RNA per malattie rare.
BTB Therapeutics, una empresa de desarrollo de fármacos en etapa clínica que trabaja en medicamentos para el dolor no opioides ENDOPIN, ha anunciado dos nuevas incorporaciones a su junta directiva. David R. Snyder, un socio retirado de Pillsbury Winthrop Shaw Pittman LLP con más de 30 años de experiencia en finanzas corporativas y fusiones y adquisiciones, y Dr. Nobuhiro Yagi, Oficial Ejecutivo en Kyoto University Innovation Capital, se han unido a la junta.
Snyder, que actualmente se desempeña como Vicepresidente y Director Independiente Principal en PriceSmart (PSMT), aporta una amplia experiencia legal y en gobernanza corporativa. El Dr. Yagi contribuye con 18 años de experiencia en I+D biofarmacéutica y desarrollo de negocios en Kyowa Kirin, junto con experiencia en investigación de varias instituciones prestigiosas.
Ambos nombramientos están alineados con el enfoque de BTB en el desarrollo de analgésicos no opioides y modificadores de empalme de ARN para enfermedades raras.
BTB Therapeutics, 비오피오이드 통증 치료제 ENDOPIN을 개발 중인 임상 단계의 제약 회사가 이사회를 두 명의 새로운 이사로 추가했다고 발표했습니다. David R. Snyder, Pillsbury Winthrop Shaw Pittman LLP의 은퇴한 파트너로, 30년 이상의 기업 금융 및 M&A 경험을 보유하고 있으며, Dr. Nobuhiro Yagi, 교토대학교 혁신 자본의 전무이사, 이사회에 합류했습니다.
Snyder는 현재 PriceSmart (PSMT)에서 부회장 및 수석 독립 이사로 재직하며, 폭넓은 법률 전문성과 기업 거버넌스 경험을 제공합니다. Dr. Yagi는 Kyowa Kirin에서 생물 제약 R&D 및 사업 개발 분야에서 18년의 경험을 가지고 있으며, 여러 저명한 기관에서의 연구 경험도 보유하고 있습니다.
두 임명 모두 BTB가 비오피오이드 진통제 및 희귀 질환을 위한 RNA 스플라이싱 수정제를 개발하는 데 집중하고 있다는 점과 일치합니다.
BTB Therapeutics, une entreprise de développement pharmaceutique en phase clinique travaillant sur des médicaments antidouleur non opioïdes ENDOPIN, a annoncé deux nouvelles nominations au sein de son conseil d'administration. David R. Snyder, un partenaire à la retraite de Pillsbury Winthrop Shaw Pittman LLP avec plus de 30 ans d'expérience en finance d'entreprise et en fusions-acquisitions, et Dr. Nobuhiro Yagi, Directeur Exécutif chez Kyoto University Innovation Capital, ont rejoint le conseil.
Snyder, qui occupe actuellement le poste de Vice-Président et de Directeur Indépendant Principal chez PriceSmart (PSMT), apporte une vaste expertise juridique et une expérience en gouvernance d'entreprise. Le Dr. Yagi contribue avec 18 ans d'expérience en R&D biopharmaceutique et en développement commercial chez Kyowa Kirin, ainsi qu'une expérience de recherche dans diverses institutions prestigieuses.
Ces deux nominations s'inscrivent dans l'axe de BTB visant à développer des analgésiques non opioïdes et des modificateurs d'épissage d'ARN pour les maladies rares.
BTB Therapeutics, ein Unternehmen für die Entwicklung von Arzneimitteln in der klinischen Phase, das an nicht-opioiden Schmerzmitteln ENDOPIN arbeitet, hat zwei neue Mitglieder in seinen Vorstand berufen. David R. Snyder, ein pensionierter Partner von Pillsbury Winthrop Shaw Pittman LLP mit über 30 Jahren Erfahrung in Unternehmensfinanzierung und M&A, sowie Dr. Nobuhiro Yagi, Executive Officer bei Kyoto University Innovation Capital, sind dem Vorstand beigetreten.
Snyder, der derzeit als Vizepräsident und leitender unabhängiger Direktor bei PriceSmart (PSMT) tätig ist, bringt umfangreiche rechtliche Expertise und Erfahrung in der Unternehmensführung mit. Dr. Yagi bringt 18 Jahre Erfahrung in der biopharmazeutischen F&E und Geschäftsentwicklung von Kyowa Kirin mit, sowie Forschungserfahrung von verschiedenen renommierten Institutionen.
Beide Ernennungen stehen im Einklang mit BTBs Fokus auf die Entwicklung von nicht-opioiden Analgetika und RNA-Spleißmodifikatoren für seltene Krankheiten.
- Strategic board appointments bringing expertise in corporate finance, M&A, and biopharmaceutical R&D
- Addition of experienced public company director (PSMT Vice Chairman)
- Strengthened connection to academic research through Dr. Yagi's affiliations
- None.
Mr. Snyder retired as a partner with Pillsbury Winthrop Shaw Pittman LLP effective January 1, 2025. Mr. Snyder was a lawyer in the firm’s Corporate & Securities practice for over 30 years, focusing on corporate finance and mergers and acquisitions for both private and public companies. For the past several years he has held an adjunct faculty appointment at the University of San Diego School of Law. Mr. Snyder holds a Doctor of Law degree from Cornell University and a Bachelor of Arts from Michigan State University. He is NACD Directorship Certified®. Mr. Snyder has served on the Board of Directors of PriceSmart, Inc. (Nasdaq: PSMT) since 2021 and currently is Vice Chairman and Lead Independent Director.
Dr. Yagi is Executive Officer and General Manager of Investment Department I at Kyoto University Innovation Capital Co., Ltd. (
“Dave and Nobu are exceptional leaders with a wealth of experience in life science investment and management. They will be instrumental as we advance our pipeline of first-in-class non-opioid analgesic compound, ENDOPIN,” said Takashi Kiyoizumi, MD, PhD, CEO of BTB Therapeutics.
“I am honored to join the BTB Therapeutics, Inc. board and support the company’s vision of addressing significant unmet needs in non-opioid analgesics and in rare disease,” said Mr. Snyder.
Dr. Yagi said, “BTB’s focus on novel non-opioid therapies and novel RNA splicing modifiers resonates with our investment thesis to bring innovative therapeutics in the areas of significant unmet needs.”
About BTB Therapeutics, Inc.
BTB Therapeutics, Inc., a Delaware C-corp., was established as BTB Therapeutics Co., Ltd. in
We are engaged in the research and development of ENDOPIN, a first-in-class non-opioid analgesic, as well as small molecules targeting abnormal RNA splicings for the treatment of rare diseases and cancer immunotherapy. Since our inception, in addition to VC investments, we have been awarded multiple grants from the Japan Agency for Medical Research and Development (AMED) and
For more information, please visit www.btbtherapeutics.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250224868759/en/
Takashi Kiyoizumi, MD, PhD.
Chief Executive Officer
BTB Therapeutics, Inc.
info@btbtherapeutics.com
Source: BTB Therapeutics, Inc.
FAQ
Who are the new board members appointed to BTB Therapeutics in 2025?
What is BTB Therapeutics' main product under development?
What is David Snyder's current role at PriceSmart (PSMT)?
What is Dr. Nobuhiro Yagi's background in pharmaceutical industry?
